BiologicalDrug
Rasdegafusp alfa clinical trials
Also written CDX-1401 and DEC-205/NY-ESO-1 Fusion Protein CDX-1401.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How studies write it
Studies that test it under each name
Development codes
Other names
Combined with it in one product
Studies by the year they started
7 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2013 | 1 |
| 2015 | 2 |
| 2017 | 2 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 5
Roswell Park Cancer Institute (2) · Celldex Therapeutics (2) · National Cancer Institute (NCI) (1) · Yale University (1) · Case Comprehensive Cancer Center (1)
Often tested with
Tested in the same studies.
Poly ICLC (3) · Decitabine (2) · Nivolumab (1) · Guadecitabine (1) · Varlilumab (1) · Ipilimumab (1) · Atezolizumab (1) · Pembrolizumab (1)
Studies
Open first, then newest update. How each study uses rasdegafusp alfa is read from its arms, and is right about nine times in ten.
Testing it · 7
- Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedPhase 1/2National Cancer Institute (NCI)NCT03206047Written as DEC-205/NY-ESO-1 Fusion Protein CDX-1401
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedPhase 1Roswell Park Cancer InstituteNCT03358719Written as DEC-205/NY-ESO-1 Fusion Protein CDX-1401
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedPhase 1Roswell Park Cancer InstituteNCT01834248Written as DEC-205/NY-ESO-1 Fusion Protein CDX-1401
- Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung CancerWithdrawnPhase 2Yale UniversityNCT02495636Written as CDX-1401
- A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV MelanomaTerminatedPhase 1/2Celldex TherapeuticsNCT02413827Written as Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC
- A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor PatientsWithdrawnPhase 1/2Case Comprehensive Cancer CenterNCT02661100Written as CDX-1401
- A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1CompletedPhase 1/2Celldex TherapeuticsNCT00948961Written as CDX-1401
Given in every arm · 3 — rasdegafusp alfa is usual care beside what is tested
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in RemissionCompletedPhase 1/2Roswell Park Cancer InstituteNCT02166905Written as DEC-205/NY-ESO-1 Fusion Protein CDX-1401
- A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV MelanomaCompletedPhase 2National Cancer Institute (NCI)NCT02129075Written as DEC-205/NY-ESO-1 Fusion Protein CDX-1401
- Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsCompletedPhase 1Roswell Park Cancer InstituteNCT01522820Written as DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Codes
What other systems call rasdegafusp alfa · ClinicalTrials.gg INT017942
- UNII (FDA) SU9AMV39DBRASDEGAFUSP ALFAOne source FDA
- NCI Thesaurus C170362Rasdegafusp AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | SU9AMV39DB | RASDEGAFUSP ALFA | One source FDA |
| NCI Thesaurus | C170362 | Rasdegafusp Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.